Roberto Trasolini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Roberto Trasolini has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Brian Bressler
Department of Gastroenterology, University of British Columbia , Vancouver, BC V6B0C3 , Canada
2 shared publicationsCherry Galorport
St. Paul's Hospital Division of Gastroenterology Vancouver, BC V6Z1Y6
2 shared publicationsGregory Rosenfeld
Department of Gastroenterology, University of British Columbia , Vancouver, BC V6B0C3 , Canada
2 shared publications- Natasha Klemm
Department of Medicine, University of British Columbia , Vancouver, BC
2 shared publications Ahmer A Karimuddin
University of British Columbia Department of Surgery, St. Paul’s Hospital Vancouver, BC V5Z 1M9
1 shared publicationAlberto Larghi
Digestive Endoscopy Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7) , e70275
EUS‐Guided Gallbladder Drainage for Acute Cholecystitis in the Western World: Heterogeneity in Current Practice and the Relation With Patient Outcome
Background: Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis (AC), but some patients are unfit for (immediate) surgery. Endoscopic ultrasound‐guided gallbladder drainage (EUS‐GBD) using a lumen‐apposing metal stent (LAMS) is increasingly used in this population. Objective: This multicenter cohort study aimed to evaluate practice patterns in EUS‐GBD across Western centers and to identify factors that influence outcomes. Design: We retrospectively analyzed data from patients undergoing EUS‐GBD for AC across 18 centers. Patient‐related, procedural and outcome data were collected. The primary outcomes of interest were LAMS‐related adverse events (AEs), recurrent biliary disease, recurrent acute cholecystitis, and all‐cause mortality. Time‐to‐event analyses were performed using center‐stratified Cox proportional hazards and Fine–Gray competing‐risk models to identify LAMS procedural factors associated with clinical outcomes. Results: We included 496 patients with a median follow‐up of 176 days (IQR 44–569). Technical and clinical success rates of EUS‐GBD were 98.2% and 93.5%, respectively. LAMS‐related AEs and recurrent biliary disease occurred in 11.1% and 18.8% of patients, respectively. Transduodenal access was associated with a lower cumulative incidence of LAMS‐related AEs compared with transgastric access (SHR 0.42, 95% CI 0.23–0.76, p = 0.004) and lower rates of recurrent biliary disease and recurrent acute cholecystitis during follow‐up. Larger LAMS diameters (> 10 mm) were associated with a lower risk of recurrent acute cholecystitis and all‐cause mortality. No association between coaxial DPPS placement and improved long‐term outcomes could be demonstrated after competing‐risk adjustment. Among patients undergoing interval cholecystectomy ( N = 46), LAMS‐related conversion from laparoscopy to laparotomy occurred in 3 cases (6.5%). Conclusions: In this large cohort study, transduodenal access route and choice of a large (> 10 mm) LAMS diameter were associated with improved outcomes of EUS‐GBD. EUS‐GBD may be a feasible option as a bridge to laparoscopic cholecystectomy, with limited risk of conversion to laparotomy. The findings of our study require prospective validation.
- 13 August 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7) , e70275
Open AccessEUS‐Guided Gallbladder Drainage for Acute Cholecystitis in the Western World: Heterogeneity in Current Practice and the Relation With Patient Outcome
Background: Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis (AC), but some patients are unfit for (immediate) surgery. Endoscopic ultrasound‐guided gallbladder drainage (EUS‐GBD) using a lumen‐apposing metal stent (LAMS) is increasingly used in this population. Objective: This multicenter cohort study aimed to evaluate practice patterns in EUS‐GBD across Western centers and to identify factors that influence outcomes. Design: We retrospectively analyzed data from patients undergoing EUS‐GBD for AC across 18 centers. Patient‐related, procedural and outcome data were collected. The primary outcomes of interest were LAMS‐related adverse events (AEs), recurrent biliary disease, recurrent acute cholecystitis, and all‐cause mortality. Time‐to‐event analyses were performed using center‐stratified Cox proportional hazards and Fine–Gray competing‐risk models to identify LAMS procedural factors associated with clinical outcomes. Results: We included 496 patients with a median follow‐up of 176 days (IQR 44–569). Technical and clinical success rates of EUS‐GBD were 98.2% and 93.5%, respectively. LAMS‐related AEs and recurrent biliary disease occurred in 11.1% and 18.8% of patients, respectively. Transduodenal access was associated with a lower cumulative incidence of LAMS‐related AEs compared with transgastric access (SHR 0.42, 95% CI 0.23–0.76, p = 0.004) and lower rates of recurrent biliary disease and recurrent acute cholecystitis during follow‐up. Larger LAMS diameters (> 10 mm) were associated with a lower risk of recurrent acute cholecystitis and all‐cause mortality. No association between coaxial DPPS placement and improved long‐term outcomes could be demonstrated after competing‐risk adjustment. Among patients undergoing interval cholecystectomy ( N = 46), LAMS‐related conversion from laparoscopy to laparotomy occurred in 3 cases (6.5%). Conclusions: In this large cohort study, transduodenal access route and choice of a large (> 10 mm) LAMS diameter were associated with improved outcomes of EUS‐GBD. EUS‐GBD may be a feasible option as a bridge to laparoscopic cholecystectomy, with limited risk of conversion to laparotomy. The findings of our study require prospective validation.
- Open Access
- 27 February 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 9 (3) , 180-185
Determinants and outcomes of early cholecystectomy for mild gallstone pancreatitis in British Columbia, Canada
Background: Early cholecystectomy is recommended for patients with gallstone pancreatitis to reduce recurrent gallstone-related adverse events. However, the management of patients with gallstone pancreatitis in British Columbia (BC) is not known. This study aims to determine the prevalence of early cholecystectomy and outcomes among patients admitted in BC with mild gallstone pancreatitis. Methods: A retrospective multicentre cohort of patients with gallstone pancreatitis admitted from 2018 to 2023 to 4 BC hospitals. Exclusion criteria included prior cholecystectomy, pancreatic cancer, and patients with moderate or severe pancreatitis. Patients receiving a cholecystectomy in ≤30 days were labelled early and compared to late cholecystectomy (>30 days) or no cholecystectomy. The primary outcome was recurrent biliary events, including cholecystitis, choledocholithiasis, and pancreatitis. Results: In total, 260 patients were included in the analysis and 35.0% had early cholecystectomy. Early cholecystectomy was associated with younger age (53.0 years vs 65.4 years, P < .001) and fewer comorbidities (Charlson Comorbidity Index 1.6 vs 3.3, P < .001) in univariate analysis. Multivariate analysis identified nonsurgical admission to gastroenterology (OR, 0.16; 95% CI, 0.06-0.44; P < .001) or other services (OR, 0.07; 95% CI, 0.028-0.17; P < .001) as less likely to result in early cholecystectomy. Patients who received late cholecystectomy were more likely to experience recurrent biliary events in univariate (HR, 3.16; 95% CI, 1.93-5.20; P < .001) and multivariate Cox-regression analysis (HR, 4.36; 95% CI, 1.9-10.1). Conclusions: Early cholecystectomy reduces recurrent biliary events. Admission under surgery is associated with early cholecystectomy and may be important in achieving higher rates of index admission cholecystectomy.
- 27 February 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 9 (3) , 180-185
Open AccessDeterminants and outcomes of early cholecystectomy for mild gallstone pancreatitis in British Columbia, Canada
Background: Early cholecystectomy is recommended for patients with gallstone pancreatitis to reduce recurrent gallstone-related adverse events. However, the management of patients with gallstone pancreatitis in British Columbia (BC) is not known. This study aims to determine the prevalence of early cholecystectomy and outcomes among patients admitted in BC with mild gallstone pancreatitis. Methods: A retrospective multicentre cohort of patients with gallstone pancreatitis admitted from 2018 to 2023 to 4 BC hospitals. Exclusion criteria included prior cholecystectomy, pancreatic cancer, and patients with moderate or severe pancreatitis. Patients receiving a cholecystectomy in ≤30 days were labelled early and compared to late cholecystectomy (>30 days) or no cholecystectomy. The primary outcome was recurrent biliary events, including cholecystitis, choledocholithiasis, and pancreatitis. Results: In total, 260 patients were included in the analysis and 35.0% had early cholecystectomy. Early cholecystectomy was associated with younger age (53.0 years vs 65.4 years, P < .001) and fewer comorbidities (Charlson Comorbidity Index 1.6 vs 3.3, P < .001) in univariate analysis. Multivariate analysis identified nonsurgical admission to gastroenterology (OR, 0.16; 95% CI, 0.06-0.44; P < .001) or other services (OR, 0.07; 95% CI, 0.028-0.17; P < .001) as less likely to result in early cholecystectomy. Patients who received late cholecystectomy were more likely to experience recurrent biliary events in univariate (HR, 3.16; 95% CI, 1.93-5.20; P < .001) and multivariate Cox-regression analysis (HR, 4.36; 95% CI, 1.9-10.1). Conclusions: Early cholecystectomy reduces recurrent biliary events. Admission under surgery is associated with early cholecystectomy and may be important in achieving higher rates of index admission cholecystectomy.
- Open Access
- 31 July 2024
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 7 (5) , 376-383
Motivations behind complementary and alternative medicine use in patients with Crohn’s disease and ulcerative colitis
Background: Complementary and alternative medicine (CAM) use is common in inflammatory bowel disease (IBD) patients and impacts compliance with conventional treatment. Gastroenterologists should understand the motivational factors of CAM use—factors that push patients away from standard therapy or pull towards CAM. Our study describes the motivations behind CAM use for IBD and evaluates differences between Crohn’s disease (CD) and ulcerative colitis (UC) patients. Methods: Retrospective cohort survey of patients over 18 years old with IBD, evaluated by gastroenterologists at a tertiary care referral centre from January 1 to December 31, 2019. Only patients who reported CAM use were included. Chi-square and independent t-tests were performed and P-value <0.05 was significant. Results: Of the 230 completed surveys, 193 reported CAM use (CD: 57.5% vs UC: 42.5%). Demographics, disease duration, and hospitalizations were similar, but CD patients had lower SIBDQ scores (CD: 48.1 vs UC: 53.5, P < 0.001). Both groups were largely influenced by their social network to use CAM (CD: 33% vs UC: 31.3%) and did not feel well informed about CAM (87.4%). CD and UC patients had similar push and pull factors. Push factors included lack of improvement (39%) and side effects (20%) with conventional treatment. Pull factors included the desire for a holistic approach (21%) and to improve mood (35%). UC patients wanted a natural approach to treat their IBD, which nearly reached significance (P = 0.049). Most patients hoped fatigue 62.7%, and diarrhoea 61.7% would improve with CAM, but more CD patients wanted to improve their appetite (P = 0.043). Conclusion: Despite differences in QoL, push and pull motivations for CAM use did not differ between CD and UC patients. Most users do not feel well informed of CAM and ongoing dialogue is important for patient-centred care.
- 31 July 2024
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 7 (5) , 376-383
Open AccessMotivations behind complementary and alternative medicine use in patients with Crohn’s disease and ulcerative colitis
Background: Complementary and alternative medicine (CAM) use is common in inflammatory bowel disease (IBD) patients and impacts compliance with conventional treatment. Gastroenterologists should understand the motivational factors of CAM use—factors that push patients away from standard therapy or pull towards CAM. Our study describes the motivations behind CAM use for IBD and evaluates differences between Crohn’s disease (CD) and ulcerative colitis (UC) patients. Methods: Retrospective cohort survey of patients over 18 years old with IBD, evaluated by gastroenterologists at a tertiary care referral centre from January 1 to December 31, 2019. Only patients who reported CAM use were included. Chi-square and independent t-tests were performed and P-value <0.05 was significant. Results: Of the 230 completed surveys, 193 reported CAM use (CD: 57.5% vs UC: 42.5%). Demographics, disease duration, and hospitalizations were similar, but CD patients had lower SIBDQ scores (CD: 48.1 vs UC: 53.5, P < 0.001). Both groups were largely influenced by their social network to use CAM (CD: 33% vs UC: 31.3%) and did not feel well informed about CAM (87.4%). CD and UC patients had similar push and pull factors. Push factors included lack of improvement (39%) and side effects (20%) with conventional treatment. Pull factors included the desire for a holistic approach (21%) and to improve mood (35%). UC patients wanted a natural approach to treat their IBD, which nearly reached significance (P = 0.049). Most patients hoped fatigue 62.7%, and diarrhoea 61.7% would improve with CAM, but more CD patients wanted to improve their appetite (P = 0.043). Conclusion: Despite differences in QoL, push and pull motivations for CAM use did not differ between CD and UC patients. Most users do not feel well informed of CAM and ongoing dialogue is important for patient-centred care.
- Open Access
- 30 March 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (2) , 181-190
Cryotherapy versus radiofrequency ablation in the treatment of dysplastic Barrett’s esophagus with or without early esophageal neoplasia: a systematic review and meta-analysis
Background/Aims: Radiofrequency ablation (RFA) is the first-line therapy for dysplastic Barrett’s esophagus (BE). Therefore, cryotherapy has emerged as an alternative treatment option. This study aimed to compare the efficacies of these two techniques based on the rates of complete eradication of intestinal metaplasia (CE-IM) and dysplasia (CE-D). Adverse events and recurrence have also been reported.Methods: An electronic search was conducted using the Medline (PubMed), Embase, LILACS, and Google Scholar databases until December 2022. Studies were included comparing cryotherapy and RFA for treating dysplastic BE with or without early esophageal neoplasia. This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.Results: Three retrospective cohort studies involving 627 patients were included. Of these, 399 patients underwent RFA, and 228 were treated with cryotherapy. There was no difference in CE-IM (risk difference [RD], –0.03; 95% confidence interval [CI], –0.25 to 0.19; p=0.78; I2=86%) as well as in CE-D (RD, –0.03; 95% CI, –0.15 to 0.09; p=0.64; I2=70%) between the groups. The absolute number of adverse events was low, and there was no difference in the recurrence rate.Conclusions: Cryotherapy and RFA were equally effective in treating dysplastic BE, with or without early esophageal neoplasia.
- 30 March 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (2) , 181-190
Open AccessCryotherapy versus radiofrequency ablation in the treatment of dysplastic Barrett’s esophagus with or without early esophageal neoplasia: a systematic review and meta-analysis
Background/Aims: Radiofrequency ablation (RFA) is the first-line therapy for dysplastic Barrett’s esophagus (BE). Therefore, cryotherapy has emerged as an alternative treatment option. This study aimed to compare the efficacies of these two techniques based on the rates of complete eradication of intestinal metaplasia (CE-IM) and dysplasia (CE-D). Adverse events and recurrence have also been reported.Methods: An electronic search was conducted using the Medline (PubMed), Embase, LILACS, and Google Scholar databases until December 2022. Studies were included comparing cryotherapy and RFA for treating dysplastic BE with or without early esophageal neoplasia. This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.Results: Three retrospective cohort studies involving 627 patients were included. Of these, 399 patients underwent RFA, and 228 were treated with cryotherapy. There was no difference in CE-IM (risk difference [RD], –0.03; 95% confidence interval [CI], –0.25 to 0.19; p=0.78; I2=86%) as well as in CE-D (RD, –0.03; 95% CI, –0.15 to 0.09; p=0.64; I2=70%) between the groups. The absolute number of adverse events was low, and there was no difference in the recurrence rate.Conclusions: Cryotherapy and RFA were equally effective in treating dysplastic BE, with or without early esophageal neoplasia.
- 1 July 2021
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 45 (4) , 101604
Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis
- 1 July 2021
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 45 (4) , 101604
Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis
- Open Access
- 1 January 2021
- Published by Kare Publishing in Hepatology Forum
- Vol. 2 (3) , 117-119
De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor
Liver transplant donors and recipients are routinely screened for hepatitis B virus (HBV) infection by measuring the levels of hepatitis B surface antigen (HBsAg) and hepatitis B core (anti-HBc) antibodies. Organs are accepted from donors who are HB-negative, and increased monitoring is required for organs from donors considered at increased risk. Transplant recipients are vaccinated if there is no sign of previous infection or immunity and monitored for reactivation in case of previous HBV infection. In cases where both the donor and the recipient are HBV-negative, no antiviral prophylaxis is used post transplant. This report describes a case of an HBV-immunized, anti-HBc-negative patient who underwent an orthotopic liver transplant from an anti-HBc-negative donor. The patient did not receive post-transplant antiviral prophylaxis due to mutual anti-HBc-seronegative status. However, the recipient developed HBV infection with isolated HBsAg and persistently negative anti-HBc. Mutations in the core/pre-core regions of the HBV gene were not implicated for unique serology in this case. Immunosuppression post liver transplant is the likely etiology for isolated HBsAg seroconversion despite significantly elevated HBV DNA. Our experience suggests that HBV DNA screening of liver transplant donors and recipients, in addition to HBV DNA monitoring of recipients, may reduce the risk of transplant-associated HBV.
- 1 January 2021
- Published by Kare Publishing in Hepatology Forum
- Vol. 2 (3) , 117-119
Open AccessDe novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor
Liver transplant donors and recipients are routinely screened for hepatitis B virus (HBV) infection by measuring the levels of hepatitis B surface antigen (HBsAg) and hepatitis B core (anti-HBc) antibodies. Organs are accepted from donors who are HB-negative, and increased monitoring is required for organs from donors considered at increased risk. Transplant recipients are vaccinated if there is no sign of previous infection or immunity and monitored for reactivation in case of previous HBV infection. In cases where both the donor and the recipient are HBV-negative, no antiviral prophylaxis is used post transplant. This report describes a case of an HBV-immunized, anti-HBc-negative patient who underwent an orthotopic liver transplant from an anti-HBc-negative donor. The patient did not receive post-transplant antiviral prophylaxis due to mutual anti-HBc-seronegative status. However, the recipient developed HBV infection with isolated HBsAg and persistently negative anti-HBc. Mutations in the core/pre-core regions of the HBV gene were not implicated for unique serology in this case. Immunosuppression post liver transplant is the likely etiology for isolated HBsAg seroconversion despite significantly elevated HBV DNA. Our experience suggests that HBV DNA screening of liver transplant donors and recipients, in addition to HBV DNA monitoring of recipients, may reduce the risk of transplant-associated HBV.
- Open Access
- 19 November 2020
- Published by Wiley in Digestive Endoscopy
- Vol. 33 (2) , 290-297
Artificial intelligence and deep learning for small bowel capsule endoscopy
Capsule endoscopy is ideally suited to artificial intelligence‐based interpretation given its reliance on pattern recognition in still images. Time saving viewing modes and lesion detection features currently available rely on machine learning algorithms, a form of artificial intelligence. Current software necessitates close human supervision given poor sensitivity relative to an expert reader. However, with the advent of deep learning, artificial intelligence is becoming increasingly reliable and will be increasingly relied upon. We review the major advances in artificial intelligence for capsule endoscopy in recent publications and briefly review artificial intelligence development for historical understanding. Importantly, recent advancements in artificial intelligence have not yet been incorporated into practice and it is immature to judge the potential of this technology based on current platforms. Remaining regulatory and standardization hurdles are being overcome and artificial intelligence‐based clinical applications are likely to proliferate rapidly.
- 19 November 2020
- Published by Wiley in Digestive Endoscopy
- Vol. 33 (2) , 290-297
Open AccessArtificial intelligence and deep learning for small bowel capsule endoscopy
Capsule endoscopy is ideally suited to artificial intelligence‐based interpretation given its reliance on pattern recognition in still images. Time saving viewing modes and lesion detection features currently available rely on machine learning algorithms, a form of artificial intelligence. Current software necessitates close human supervision given poor sensitivity relative to an expert reader. However, with the advent of deep learning, artificial intelligence is becoming increasingly reliable and will be increasingly relied upon. We review the major advances in artificial intelligence for capsule endoscopy in recent publications and briefly review artificial intelligence development for historical understanding. Importantly, recent advancements in artificial intelligence have not yet been incorporated into practice and it is immature to judge the potential of this technology based on current platforms. Remaining regulatory and standardization hurdles are being overcome and artificial intelligence‐based clinical applications are likely to proliferate rapidly.
- Open Access
- 4 September 2019
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 3 (6) , 274-278
Internet-Based Patient Education Prior to Colonoscopy: Prospective, Observational Study of a Single Center’s Implementation, with Objective Assessment of Bowel Preparation Quality and Patient Satisfaction
Background: Nonpharmacologic factors, including patient education, affect bowel preparation for colonoscopy. Optimal cleansing increases quality and reduces repeat procedures. This study prospectively analyzes use of an individualized online patient education module in place of traditional patient education. Aims: To determine the effectiveness of online education for patients, measured by the proportion achieving sufficient bowel preparation. Secondary measures include assessment of patient satisfaction. Methods: Prospective, single-center, observational study. Adults aged 19 years and over, with an e-mail account, scheduled for nonurgent colonoscopy, with English proficiency (or someone who could translate for them) were recruited. Demographics and objective bowel preparation quality were collected. Patient satisfaction was assessed via survey to assess clarity and usefulness of the module. Results: Nine hundred consecutive patients completed the study. 84.6% of patients achieved adequate bowel preparation as measured by Boston bowel preparation score ≥ 6 and 90.1% scored adequately using Ottawa bowel preparation score ≤7. 94.2% and 92.1% of patients rated the web-education module as ‘very useful’ and ‘very clear’, respectively (≥8/10 on respective scales). Conclusions: Our analysis suggests that internet-based patient education prior to colonoscopy is a viable option and achieves adequate bowel preparation. Preparation quality is comparable to previously published trials. Included patients found the process clear and useful. Pragmatic benefits of a web-based protocol such as time and cost savings were not formally assessed but may contribute to greater satisfaction for endoscopists and patients.
- 4 September 2019
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 3 (6) , 274-278
Open AccessInternet-Based Patient Education Prior to Colonoscopy: Prospective, Observational Study of a Single Center’s Implementation, with Objective Assessment of Bowel Preparation Quality and Patient Satisfaction
Background: Nonpharmacologic factors, including patient education, affect bowel preparation for colonoscopy. Optimal cleansing increases quality and reduces repeat procedures. This study prospectively analyzes use of an individualized online patient education module in place of traditional patient education. Aims: To determine the effectiveness of online education for patients, measured by the proportion achieving sufficient bowel preparation. Secondary measures include assessment of patient satisfaction. Methods: Prospective, single-center, observational study. Adults aged 19 years and over, with an e-mail account, scheduled for nonurgent colonoscopy, with English proficiency (or someone who could translate for them) were recruited. Demographics and objective bowel preparation quality were collected. Patient satisfaction was assessed via survey to assess clarity and usefulness of the module. Results: Nine hundred consecutive patients completed the study. 84.6% of patients achieved adequate bowel preparation as measured by Boston bowel preparation score ≥ 6 and 90.1% scored adequately using Ottawa bowel preparation score ≤7. 94.2% and 92.1% of patients rated the web-education module as ‘very useful’ and ‘very clear’, respectively (≥8/10 on respective scales). Conclusions: Our analysis suggests that internet-based patient education prior to colonoscopy is a viable option and achieves adequate bowel preparation. Preparation quality is comparable to previously published trials. Included patients found the process clear and useful. Pragmatic benefits of a web-based protocol such as time and cost savings were not formally assessed but may contribute to greater satisfaction for endoscopists and patients.